Reported Earnings • May 19
First quarter 2026 earnings released: NT$0.54 loss per share (vs NT$0.34 loss in 1Q 2025) First quarter 2026 results: NT$0.54 loss per share (further deteriorated from NT$0.34 loss in 1Q 2025). Revenue: NT$151.8m (up 25% from 1Q 2025). Net loss: NT$39.1m (loss widened 60% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year. Anuncio • May 13
Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million. Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 5,437,000
Price\Range: TWD 22.06
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,115,000
Price\Range: TWD 22.2 New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.62b market cap, or US$51.4m). Reported Earnings • Apr 07
Full year 2025 earnings released: NT$0.54 loss per share (vs NT$3.08 loss in FY 2024) Full year 2025 results: NT$0.54 loss per share (improved from NT$3.08 loss in FY 2024). Revenue: NT$708.4m (up 47% from FY 2024). Net loss: NT$39.4m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Anuncio • Apr 02
Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million. Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 7,552
Price(maximum): TWD 25 Anuncio • Mar 17
Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026 Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan Anuncio • Nov 11
Genomics Has Announces New Research Genomics has announced new research that suggests polygenic risk scores (PRS) can significantly improve the predictive performance of the cardiovascular disease (CVD) risk prediction tool, PREVENT. The findings were presented at the American Heart Association Conference 2025. The research shows that adding genetic risk to CVD tools can better identify individuals at risk of heart disease, with this benefit seen across ancestries. The findings support the implementation of PRS with the next generation of clinical CVD risk predictors, adding to a growing body of evidence that PRS can help improve CVD prevention, saving patient lives and improving population health. CVD is the leading cause of death in the U.S., claiming over 900,000 lives in 2023, accounting for approximately one in three deaths. There is one CVD death every 34 seconds, and someone has a heart attack every 40 seconds. The cost of heart disease in the U.S. in 2024 was over $400 billion. The key to CVD prevention is to identify people at high risk of the disease and to reduce their risk through statin therapy and lifestyle changes. The widespread use of statins for CVD prevention earlier this century has dramatically reduced CVD deaths. A meta-analysis of 25 trials involving nearly 70,000 patients with coronary heart disease found that the use of statins reduces CVD events by 25% and overall mortality by 16%. Previous studies had shown that adding polygenic risk to earlier clinical risk calculators significantly improves risk prediction for CVD. Further, 8% of individuals aged 40-69 were reclassified as higher risk in the IRT compared to PREVENT alone. These high-risk individuals are not currently flagged by PREVENT. Using these calculations, the researchers also found that over three million people aged 40-70 in the U.S. at high risk of CVD are currently invisible to the system, because genetics is not being used as part of CVD risk prediction measures. Statins are even more effective than average for people with high PRS. This means that over 100,000 people could avoid CVD-related complications over ten years if PRS were routinely added to PREVENT, followed by statin treatment for the newly classified high-risk individuals (compared to these individuals not being treated with statins). This study adds to a growing body of data that PRS can help improveCVD management and prevention. Genomics's 2021 HEART clinical trial, conducted with the United Kingdom's National Health Service (NHS), demonstrated that integrating genetic data into cardiovascular risk assessments fitted smoothly into clinical care pathways and changed patient management. The recently released 10-year plan for the NHS committed to rolling out prevention based on PRS to the whole country. New Risk • Sep 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$264m free cash flow). Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$2.03b market cap, or US$67.1m). Anuncio • Mar 17
Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025 Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan New Risk • Feb 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-NT$289m). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.39b market cap, or US$42.4m). Reported Earnings • Apr 16
Full year 2023 earnings released: NT$2.36 loss per share (vs NT$1.13 profit in FY 2022) Full year 2023 results: NT$2.36 loss per share (down from NT$1.13 profit in FY 2022). Revenue: NT$396.1m (down 5.5% from FY 2022). Net loss: NT$168.1m (down 335% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Anuncio • Mar 22
Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024 Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024. New Risk • Feb 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (NT$1.44b market cap, or US$45.6m). Upcoming Dividend • Aug 01
Upcoming dividend of NT$0.10 per share at 0.4% yield Eligible shareholders must have bought the stock before 08 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 8.7% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (2.8%). Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to NT$25.70, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 44x in the Biotechs industry in Taiwan. Total returns to shareholders of 4.0% over the past three years. Reported Earnings • Apr 26
Full year 2022 earnings released: EPS: NT$1.15 (vs NT$0.32 in FY 2021) Full year 2022 results: EPS: NT$1.15 (up from NT$0.32 in FY 2021). Revenue: NT$419.0m (up 7.4% from FY 2021). Net income: NT$71.6m (up 282% from FY 2021). Profit margin: 17% (up from 4.8% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment improved over the past week After last week's 100% share price gain to NT$20.30, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 190% over the past three years. Reported Earnings • Aug 15
First half 2022 earnings released: EPS: NT$1.13 (vs NT$0.71 in 1H 2021) First half 2022 results: EPS: NT$1.13 (up from NT$0.71 in 1H 2021). Revenue: NT$205.2m (up 6.4% from 1H 2021). Net income: NT$67.9m (up 64% from 1H 2021). Profit margin: 33% (up from 21% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 27
Full year 2021 earnings released: EPS: NT$0.32 (vs NT$0.011 in FY 2020) Full year 2021 results: EPS: NT$0.32 (up from NT$0.011 in FY 2020). Revenue: NT$390.0m (down 12% from FY 2020). Net income: NT$18.7m (up NT$18.1m from FY 2020). Profit margin: 4.8% (up from 0.1% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Anuncio • Apr 02
Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022 Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment improved over the past week After last week's 18% share price gain to NT$16.95, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 20x in the Biotechs industry in Taiwan. Total returns to shareholders of 21% over the past three years. Reported Earnings • Aug 18
First half 2021 earnings released: EPS NT$0.71 (vs NT$0.027 loss in 1H 2020) The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: NT$192.9m (down 8.3% from 1H 2020). Net income: NT$41.3m (up NT$42.9m from 1H 2020). Profit margin: 21% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 28
Full year 2020 earnings released: EPS NT$0.01 (vs NT$0.31 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$443.2m (up 3.6% from FY 2019). Net income: NT$619.0k (down 97% from FY 2019). Profit margin: 0.1% (down from 4.2% in FY 2019). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Anuncio • Mar 11
Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021 Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improved over the past week After last week's 19% share price gain to NT$18.45, the stock is trading at a trailing P/E ratio of 77.6x, up from the previous P/E ratio of 65.2x. This compares to an average P/E of 40x in the Biotechs industry in Taiwan. Total return to shareholders over the past three years is a loss of 19%. Is New 90 Day High Low • Jan 28
New 90-day low: NT$16.50 The company is down 6.0% from its price of NT$17.60 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 24
New 90-day high: NT$19.50 The company is up 8.0% from its price of NT$18.00 on 26 August 2020. The Taiwanese market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is down 1.0% over the same period. 